ENOCHIAN BIOSCI. DL-0001
Lunai Bioworks Inc., a pre-clinical stage biotechnology company, engages in the development of pharmaceutical and biological products for the treatment of cancer and HIV in the United States and the Netherlands. It operates through two segments, RENB and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors… Read more
ENOCHIAN BIOSCI. DL-0001 (2Q5) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, ENOCHIAN BIOSCI. DL-0001 (2Q5) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
ENOCHIAN BIOSCI. DL-0001 - Net Assets Trend (None–None)
This chart illustrates how ENOCHIAN BIOSCI. DL-0001's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for ENOCHIAN BIOSCI. DL-0001 (None–None)
The table below shows the annual net assets of ENOCHIAN BIOSCI. DL-0001 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to ENOCHIAN BIOSCI. DL-0001's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
ENOCHIAN BIOSCI. DL-0001 Competitors by Market Cap
The table below lists competitors of ENOCHIAN BIOSCI. DL-0001 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
International Iconic Gold Exploration Corp
V:ICON
|
$1.05 Million |
|
ACS (OCI1.SG)
STU:OCI1
|
$1.05 Million |
|
Luxxfolio Holdings Inc
PINK:LUXFF
|
$1.05 Million |
|
Choheung Corp.
KQ:002600
|
$1.05 Million |
|
Direxion Daily NVDA Bull 1.5X Shares
NASDAQ:NVDU
|
$1.05 Million |
|
Arkadia Digital Media Tbk PT
JK:DIGI
|
$1.05 Million |
|
SPOBAG AG
F:SBE
|
$1.05 Million |
|
Northern Lion Gold Corp
PINK:NLGCF
|
$1.05 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ENOCHIAN BIOSCI. DL-0001's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares ENOCHIAN BIOSCI. DL-0001's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently ENOCHIAN BIOSCI. DL-0001 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares ENOCHIAN BIOSCI. DL-0001's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ENOCHIAN BIOSCI. DL-0001 (2Q5) | €- | N/A | N/A | $1.05 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |